Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent

The combined use of a TGF-beta signaling inhibitor and an antitumor active substance or an imaging agent modified by a drug-encapsulating macromolecular micelle, or the like, is provided. The selective delivery capability of the antitumor active substance or the imaging agent to the target is improved, increasing the antitumoral activity in the target.

The present invention relates to use of transforming growth factor [beta] (TGF-[beta]) signaling inhibitor, for increasing leakiness neovasculature in tumor (or cancer) tissue, and depending on the circumstances, for decreasing intratumoral fibrous components; in addition, it relates to combined use and combination of the inhibitor and an antitumor agent.

Patents:
US 20,090,186,076

Inventor(s): KATAOKA KAZUNORI [JP]; MIYAZONO KOHEI [JP]; KANO MITSUNOBU [JP]; BAE YOUNSOO [JP]; NISHIYAMA NOBUHIRO [JP]; HIRAKAWA KOSEI [JP];

Type of Offer: Sale



« More Medical Patents

---